Toh Wally, Lépine Aurélia, Gueye Khady, Fall Mame Mor, Diop Abdou Khoudia, Mbaye El Hadj Alioune, Ndour Cheikh Tidiane, O'Donnell Owen
Erasmus School of Economics, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Institute for Global Health, University College London, London, United Kingdom.
PLoS Med. 2025 Aug 18;22(8):e1004458. doi: 10.1371/journal.pmed.1004458. eCollection 2025 Aug.
HIV prevention through pre-exposure prophylaxis (PrEP) may encourage riskier sexual behaviours that undermine the protection afforded by PrEP and generate negative spillovers through sexually transmitted infections (STIs). Tests for such risk compensatory behaviour in high-risk populations, such as female sex workers (FSWs), are lacking. This study aims to assess whether risk compensatory behaviours were observed among FSWs in Senegal after the rollout of PrEP.
In a randomised controlled trial with a Zelen design, we stratified FSWs in Dakar (Senegal) by self-reported sexual risk-taking and prior PrEP experience and randomly assigned them to immediate referral for oral PrEP (Treatment) from 7 September 2021 to end January 2022 or delayed PrEP referral (Control). We compared outcomes 3-8 months after the referral of the treatment group and before the referral of the control group. Primary outcomes were self-reported condom use with clients and perceived HIV/STI risks from sex with clients with and without a condom. The analysis is a modified intention-to-treat analysis. We estimated effects of PrEP referral as well as effects of oral PrEP use induced by randomised assignment to active PrEP referral. Out of 500 individuals randomised, 308 (61.6%) were included in the analysis (Treatment: 182/300 = 60.7%; Control: 126/200 = 63%). PrEP referral increased the probability of using oral PrEP by 34.5 percentage points (pp) (95% CI [25.4, 43.6]; p < 0.001). Estimated effects of PrEP referral and PrEP use on condom use with the last client were positive but not statistically significantly different from zero. PrEP referral was estimated to increase the probability of condom use with all of the last three clients by 11.0 pp (95% CI [0.8, 21.2]; p = 0.034). PrEP use was estimated to increase this probability by 25.8 pp (95% CI [5.2, 46.4]; p = 0.014). Main limitations were low power, high attrition, self-reported outcomes and a limited follow-up period.
This study, conducted in one location, did not find evidence that PrEP referral or oral PrEP use increased self-reported risky sex behaviours of FSWs within 3-8 months. The robustness of this finding needs to be tested with larger cohorts followed for longer periods in other settings, and using survey instruments that allow further examination of whether PrEP users are more likely to overreport condom use.
ISRCTN-The UK's Clinical Study Registry, ISRCTN16445862 https://www.isrctn.com/ISRCTN16445862.
通过暴露前预防(PrEP)进行HIV预防可能会助长更具风险的性行为,从而削弱PrEP所提供的保护,并通过性传播感染(STIs)产生负面溢出效应。在女性性工作者(FSWs)等高风险人群中,缺乏针对此类风险补偿行为的测试。本研究旨在评估在塞内加尔推出PrEP后,FSWs中是否观察到风险补偿行为。
在一项采用泽伦设计的随机对照试验中,我们根据自我报告的性风险行为和既往PrEP经验对达喀尔(塞内加尔)的FSWs进行分层,并将她们随机分配为从2021年9月7日至2022年1月月底立即接受口服PrEP转介(治疗组)或延迟PrEP转介(对照组)。我们比较了治疗组转介后3至8个月以及对照组转介前的结果。主要结果是自我报告的与客户使用避孕套的情况以及与有或没有使用避孕套的客户发生性行为时感知到的HIV/STIs风险。该分析是一种改良的意向性分析。我们估计了PrEP转介的效果以及随机分配到积极PrEP转介所诱导的口服PrEP使用的效果。在随机分组的500名个体中,308名(61.6%)纳入分析(治疗组:182/300 = 60.7%;对照组:126/200 = 63%)。PrEP转介使口服PrEP的概率增加了34.5个百分点(pp)(95%置信区间[25.4, 43.6];p < 0.001)。PrEP转介和PrEP使用对与最后一名客户使用避孕套情况的估计效果为正,但与零无统计学显著差异。PrEP转介估计使与最后三名客户全部使用避孕套的概率增加了11.0 pp(95%置信区间[0.8, 21.2];p = 0.034)。PrEP使用估计使该概率增加了25.8 pp(95%置信区间[5.2, 46.4];p = 0.014)。主要局限性在于检验效能低、失访率高、自我报告结果以及随访期有限。
在一个地点进行的这项研究未发现证据表明PrEP转介或口服PrEP使用在3至8个月内增加了FSWs自我报告的危险性性行为。这一发现的稳健性需要在其他环境中使用更大的队列并进行更长时间的随访来进行检验,并且使用能够进一步检查PrEP使用者是否更有可能高估避孕套使用情况的调查工具。
ISRCTN - 英国临床研究注册库,ISRCTN16445862 https://www.isrctn.com/ISRCTN16445862